BioCentury | Nov 30, 2017
Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

...Ltd. (Tokyo:4523), Tokyo, Japan Product: Oral and IV APX001 Business: Infectious Molecular target: A. fumigatus GPI-anchored wall transfer protein 1 ( A. fumigatus GWT1...
...Treat fungal infections Endpoint: Safety; pharmacokinetics Status: Phase I data Milestone: NA Claire Quang Oral APX001 Amplyx Pharmaceuticals Inc. A. fumigatus GPI-anchored wall transfer protein 1 (A. fumigatus GWT1) C...
BioCentury | Aug 2, 2017
Financial News

Amplyx raises $67M in series C

...Tokyo:4523). Sofinnova's Anand Mehra and Lundbeckfonden's Johan Kördel will join Amplyx's board. Chris Lieu Oral APX001 Amplyx Pharmaceuticals Inc. A. fumigatus GPI-anchored wall transfer protein 1 (A. fumigatus GWT1) C...
BioCentury | Sep 19, 2016
Clinical News

IV APX001: Phase I started

...Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: IV APX001 Business: Infectious Molecular target: A. fumigatus GPI-anchored wall transfer protein 1 (A. fumigatus GWT1)...
Items per page:
1 - 3 of 3